<p>隨着我們進入 2026 年，亞洲市場正在應對一個複雜的環境，主要經濟體如中國和日本的表現參差不齊，製造業和科技行業略有增長，但經濟不確定性依然存在。在這種環境下，識別被低估的股票需要對內在價值估計保持敏鋭的關注，因為投資者在波動的市場條件中尋求潛在價值的機會。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>浙江世紀華通集團有限公司 (SZSE:002602)</td>
<td>CN¥19.06</td>
<td>CN¥37.98</td>
<td>49.8%</td>
</tr>
<tr>
<td>廈門特寶生物科技 (SHSE:688278)</td>
<td>CN¥82.07</td>
<td>CN¥161.67</td>
<td>49.2%</td>
</tr>
<tr>
<td>藥明 XDC 開曼 (SEHK:2268)</td>
<td>HK$68.40</td>
<td>HK$135.71</td>
<td>49.6%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1747.00</td>
<td>¥3449.68</td>
<td>49.4%</td>
</tr>
<tr>
<td>Mobvista (SEHK:1860)</td>
<td>HK$15.44</td>
<td>HK$30.63</td>
<td>49.6%</td>
</tr>
<tr>
<td>美圖 (SEHK:1357)</td>
<td>HK$7.42</td>
<td>HK$14.63</td>
<td>49.3%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥792.00</td>
<td>¥1577.34</td>
<td>49.8%</td>
</tr>
<tr>
<td>Contec.Co.Ltd (KOSDAQ:A451760)</td>
<td>₩14490.00</td>
<td>₩28785.36</td>
<td>49.7%</td>
</tr>
<tr>
<td>ASE 科技控股 (TWSE:3711)</td>
<td>NT$273.50</td>
<td>NT$538.87</td>
<td>49.2%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3160.00</td>
<td>¥6305.80</td>
<td>49.9%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 259 只被低估的亞洲股票的完整列表。</p>
<p>以下是篩選器中一些選擇的預覽。</p>
<h2>Morimatsu International Holdings (SEHK:2155)</h2>
<p><strong>概述：</strong> Morimatsu International Holdings Company Limited 從事化學反應、生物反應和聚合的核心設備和工藝系統的設計、製造、安裝、運營和維護，市值為 HK$128.3 億。</p>
<p><strong>運營：</strong> 該公司主要通過銷售綜合壓力設備產生收入，金額為 CN¥61.6 億。</p>
<p><strong>公允價值折扣估計：</strong> 48.6%</p>
<p>Morimatsu International Holdings 似乎被低估，當前交易價格為 HK$10.3，估計公允價值為 HK$20.05，基於折現現金流分析顯示其低於公允價值 48.6%。儘管最近內部人士大量拋售以及一位關鍵董事會成員的不幸去世影響了合規性，但該公司顯示出強大的潛力，預計年收益將顯著增長 23%，超過香港市場平均增長率 12%。</p>
<ul>
<li>根據我們最近的增長報告，Morimatsu International Holdings 的財務表現似乎有可能超過當前水平。</li>
<li>在這份財務健康報告中，獲取我們對 Morimatsu International Holdings 股票分析的全面見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:2155 截至 2026 年 1 月的折現現金流</p>
<h2>天齊鋰業 (SZSE:002466)</h2>
<p><strong>概述：</strong> 天齊鋰業股份有限公司從事鋰及鋰化合物的投資、生產、加工、提取和銷售，業務遍及澳大利亞、智利和中國，市值為 CN¥944 億。</p>
<p><strong>運營：</strong> 天齊鋰業主要通過在澳大利亞、智利和中國生產和銷售鋰、鋰濃縮物和特種鋰化合物來產生收入。</p>
<p><strong>公允價值折扣估計：</strong> 42.8%</p>
<p>天齊鋰業的交易價格為 CN¥58.62，顯著低於其估計公允價值 CN¥102.5，基於折現現金流分析顯示出顯著的低估。儘管最近高管變動和股價波動，該公司在截至 2025 年 9 月的九個月內報告了淨收入的扭轉，預計將在三年內實現盈利。收入增長預計將超過中國市場平均水平，增強其作為亞洲被低估投資機會的吸引力。</p>
<ul>
<li>我們最近的增長報告提供了對天齊鋰業商業前景的樂觀預測。</li>
<li>在我們的報告中，仔細查看天齊鋰業的資產負債表健康狀況。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b0536878-1d44-4c90-bcd8-5d8b4e9d724a/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b0536878-1d44-4c90-bcd8-5d8b4e9d724a/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:002466 截至 2026 年 1 月的折現現金流</p>
<h2>Innodisk (TPEX:5289)</h2>
<p><strong>概述：</strong> Innodisk Corporation 從事工業嵌入式存儲設備的研究、開發、製造和銷售，業務遍及多個國際市場，市值為 NT$615 億。</p>
<p><strong>運營：</strong> 該公司通過其專注於各種工業存儲設備研發的部門產生收入，金額為 NT$116.8 億。</p>
<p><strong>公允價值折扣估計：</strong> 22.5%</p>
<p>Innodisk 的交易價格為 NT$645，低於其估計公允價值 NT$832.02，基於現金流分析顯示出顯著的低估。該公司報告了 2025 年第三季度強勁的收益增長，淨收入達到 NT$643.04 百萬，而去年同期為 NT$188.62 百萬。最近與高通的合作在 AI 技術方面的產品進展增強了 Innodisk 的市場地位和超過台灣市場平均水平的收入增長潛力。</p>
<ul>
<li>我們的綜合增長報告提高了 Innodisk 實現顯著財務增長的可能性。</li>
<li>點擊這裏瞭解 Innodisk 的細節，查看我們的詳細財務健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c3a91485-32b6-4c06-ac57-53ee36cd1a5c/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c3a91485-32b6-4c06-ac57-53ee36cd1a5c/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TPEX:5289 截至 2026 年 1 月的折現現金流</p>
<h2>下一步</h2>
<ul>
<li>在這裏瀏覽基於現金流的 259 只被低估的亞洲股票的完整清單。</li>
<li>擁有這些公司的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>使用 Simply Wall St 的應用程序簡化您的投資策略，免費享受全球各地股票的廣泛研究。</li>
</ul>
<h2>尋找新的視角？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>通過顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章不應被視為財務建議。它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

特寶生物

天齊鋰業

<p>截至 2026 年 1 月，亞洲市場表現參差不齊，特別是在中國和日本。投資者正關注基於內在價值評估的被低估股票。值得關注的股票包括浙江世紀華通集團、廈門特寶生物和藥明 XDC 開曼，這些股票的公允價值均顯示出顯著折扣。森松國際控股和天齊鋰業因其增長潛力而受到關注，儘管近期面臨挑戰。文章強調了深入分析的重要性，並提供了對亞洲市場中各種被低估股票的見解</p>

<p>As we enter 2026, Asian markets are navigating a complex landscape marked by mixed performances in major economies like China and Japan, with slight gains in manufacturing and technology sectors amid ongoing economic uncertainties. In this environment, identifying undervalued stocks requires a keen focus on intrinsic valuation estimates, as investors seek opportunities that offer potential value amidst fluctuating market conditions.</p>
<div class="lb-trans"><p>隨着我們進入 2026 年，亞洲市場正在應對一個複雜的環境，主要經濟體如中國和日本的表現參差不齊，製造業和科技行業略有增長，但經濟不確定性依然存在。在這種環境下，識別被低估的股票需要對內在價值估計保持敏鋭的關注，因為投資者在波動的市場條件中尋求潛在價值的機會。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Zhejiang Century Huatong GroupLtd (SZSE:002602)</td>
<td>CN¥19.06</td>
<td>CN¥37.98</td>
<td>49.8%</td>
</tr>
<tr>
<td>Xiamen Amoytop Biotech (SHSE:688278)</td>
<td>CN¥82.07</td>
<td>CN¥161.67</td>
<td>49.2%</td>
</tr>
<tr>
<td>WuXi XDC Cayman (SEHK:2268)</td>
<td>HK$68.40</td>
<td>HK$135.71</td>
<td>49.6%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1747.00</td>
<td>¥3449.68</td>
<td>49.4%</td>
</tr>
<tr>
<td>Mobvista (SEHK:1860)</td>
<td>HK$15.44</td>
<td>HK$30.63</td>
<td>49.6%</td>
</tr>
<tr>
<td>Meitu (SEHK:1357)</td>
<td>HK$7.42</td>
<td>HK$14.63</td>
<td>49.3%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥792.00</td>
<td>¥1577.34</td>
<td>49.8%</td>
</tr>
<tr>
<td>Contec.Co.Ltd (KOSDAQ:A451760)</td>
<td>₩14490.00</td>
<td>₩28785.36</td>
<td>49.7%</td>
</tr>
<tr>
<td>ASE Technology Holding (TWSE:3711)</td>
<td>NT$273.50</td>
<td>NT$538.87</td>
<td>49.2%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3160.00</td>
<td>¥6305.80</td>
<td>49.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>浙江世紀華通集團有限公司 (SZSE:002602)</td>
<td>CN¥19.06</td>
<td>CN¥37.98</td>
<td>49.8%</td>
</tr>
<tr>
<td>廈門特寶生物科技 (SHSE:688278)</td>
<td>CN¥82.07</td>
<td>CN¥161.67</td>
<td>49.2%</td>
</tr>
<tr>
<td>藥明 XDC 開曼 (SEHK:2268)</td>
<td>HK$68.40</td>
<td>HK$135.71</td>
<td>49.6%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1747.00</td>
<td>¥3449.68</td>
<td>49.4%</td>
</tr>
<tr>
<td>Mobvista (SEHK:1860)</td>
<td>HK$15.44</td>
<td>HK$30.63</td>
<td>49.6%</td>
</tr>
<tr>
<td>美圖 (SEHK:1357)</td>
<td>HK$7.42</td>
<td>HK$14.63</td>
<td>49.3%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥792.00</td>
<td>¥1577.34</td>
<td>49.8%</td>
</tr>
<tr>
<td>Contec.Co.Ltd (KOSDAQ:A451760)</td>
<td>₩14490.00</td>
<td>₩28785.36</td>
<td>49.7%</td>
</tr>
<tr>
<td>ASE 科技控股 (TWSE:3711)</td>
<td>NT$273.50</td>
<td>NT$538.87</td>
<td>49.2%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3160.00</td>
<td>¥6305.80</td>
<td>49.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 259 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 259 只被低估的亞洲股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中一些選擇的預覽。</p>
</div><h2>Morimatsu International Holdings (SEHK:2155)</h2>
<div class="lb-trans"><h2>Morimatsu International Holdings (SEHK:2155)</h2>
</div><p><strong>Overview:</strong> Morimatsu International Holdings Company Limited is involved in the design, manufacture, installation, operation, and maintenance of core equipment and process systems for chemical reactions, biological reactions, and polymerization with a market cap of HK$12.83 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Morimatsu International Holdings Company Limited 從事化學反應、生物反應和聚合的核心設備和工藝系統的設計、製造、安裝、運營和維護，市值為 HK$128.3 億。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the sale of comprehensive pressure equipment, amounting to CN¥6.16 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過銷售綜合壓力設備產生收入，金額為 CN¥61.6 億。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 48.6%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 48.6%</p>
</div><p>Morimatsu International Holdings appears undervalued, trading at HK$10.3 against an estimated fair value of HK$20.05, suggesting it is 48.6% below fair value based on discounted cash flow analysis. Despite significant insider selling recently and the unfortunate passing of a key board member affecting compliance with listing rules, the company shows strong potential with earnings expected to grow significantly at 23% annually, outpacing Hong Kong's market average growth rate of 12%.</p>
<div class="lb-trans"><p>Morimatsu International Holdings 似乎被低估，當前交易價格為 HK$10.3，估計公允價值為 HK$20.05，基於折現現金流分析顯示其低於公允價值 48.6%。儘管最近內部人士大量拋售以及一位關鍵董事會成員的不幸去世影響了合規性，但該公司顯示出強大的潛力，預計年收益將顯著增長 23%，超過香港市場平均增長率 12%。</p>
</div><ul>
<li>In light of our recent growth report, it seems possible that Morimatsu International Holdings' financial performance will exceed current levels.</li>
<li>Unlock comprehensive insights into our analysis of Morimatsu International Holdings stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>根據我們最近的增長報告，Morimatsu International Holdings 的財務表現似乎有可能超過當前水平。</li>
<li>在這份財務健康報告中，獲取我們對 Morimatsu International Holdings 股票分析的全面見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf?theme=light"/></p>
<p>SEHK:2155 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:2155 截至 2026 年 1 月的折現現金流</p>
</div><h2>Tianqi Lithium (SZSE:002466)</h2>
<div class="lb-trans"><h2>天齊鋰業 (SZSE:002466)</h2>
</div><p><strong>Overview:</strong> Tianqi Lithium Corporation engages in the investment, production, processing, extraction, and sale of lithium and lithium compounds across Australia, Chile, and China with a market cap of CN¥94.40 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 天齊鋰業股份有限公司從事鋰及鋰化合物的投資、生產、加工、提取和銷售，業務遍及澳大利亞、智利和中國，市值為 CN¥944 億。</p>
</div><p><strong>Operations:</strong> Tianqi Lithium generates revenue primarily from the production and sale of lithium, lithium concentrate, and specialty lithium compounds in Australia, Chile, and China.</p>
<div class="lb-trans"><p><strong>運營：</strong> 天齊鋰業主要通過在澳大利亞、智利和中國生產和銷售鋰、鋰濃縮物和特種鋰化合物來產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 42.8%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 42.8%</p>
</div><p>Tianqi Lithium is trading at CN¥58.62, significantly below its estimated fair value of CN¥102.5, highlighting a substantial undervaluation based on discounted cash flow analysis. Despite recent executive changes and volatile share prices, the company reported a net income turnaround for the nine months ending September 2025 and is expected to achieve profitability within three years. Revenue growth is projected to exceed China's market average, enhancing its appeal as an undervalued investment opportunity in Asia.</p>
<div class="lb-trans"><p>天齊鋰業的交易價格為 CN¥58.62，顯著低於其估計公允價值 CN¥102.5，基於折現現金流分析顯示出顯著的低估。儘管最近高管變動和股價波動，該公司在截至 2025 年 9 月的九個月內報告了淨收入的扭轉，預計將在三年內實現盈利。收入增長預計將超過中國市場平均水平，增強其作為亞洲被低估投資機會的吸引力。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for Tianqi Lithium's business outlook.</li>
<li>Take a closer look at Tianqi Lithium's balance sheet health here in our report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們最近的增長報告提供了對天齊鋰業商業前景的樂觀預測。</li>
<li>在我們的報告中，仔細查看天齊鋰業的資產負債表健康狀況。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b0536878-1d44-4c90-bcd8-5d8b4e9d724a/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/b0536878-1d44-4c90-bcd8-5d8b4e9d724a/chart/dcf?theme=light"/></p>
<p>SZSE:002466 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SZSE:002466 截至 2026 年 1 月的折現現金流</p>
</div><h2>Innodisk (TPEX:5289)</h2>
<div class="lb-trans"><h2>Innodisk (TPEX:5289)</h2>
</div><p><strong>Overview:</strong> Innodisk Corporation is engaged in the research, development, manufacturing, and sale of industrial embedded storage devices across various international markets with a market cap of NT$61.50 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Innodisk Corporation 從事工業嵌入式存儲設備的研究、開發、製造和銷售，業務遍及多個國際市場，市值為 NT$615 億。</p>
</div><p><strong>Operations:</strong> The company generates revenue of NT$11.68 billion from its segment focused on the research and development of various industrial memory storage devices.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其專注於各種工業存儲設備研發的部門產生收入，金額為 NT$116.8 億。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 22.5%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 22.5%</p>
</div><p>Innodisk, trading at NT$645, is valued below its estimated fair value of NT$832.02, indicating a significant undervaluation based on cash flow analysis. The company reported strong earnings growth for the third quarter of 2025, with net income reaching NT$643.04 million compared to NT$188.62 million a year ago. Recent product advancements in AI technology through collaboration with Qualcomm enhance Innodisk's market position and potential for revenue growth exceeding Taiwan's market average.</p>
<div class="lb-trans"><p>Innodisk 的交易價格為 NT$645，低於其估計公允價值 NT$832.02，基於現金流分析顯示出顯著的低估。該公司報告了 2025 年第三季度強勁的收益增長，淨收入達到 NT$643.04 百萬，而去年同期為 NT$188.62 百萬。最近與高通的合作在 AI 技術方面的產品進展增強了 Innodisk 的市場地位和超過台灣市場平均水平的收入增長潛力。</p>
</div><ul>
<li>Our comprehensive growth report raises the possibility that Innodisk is poised for substantial financial growth.</li>
<li>Click here to discover the nuances of Innodisk with our detailed financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的綜合增長報告提高了 Innodisk 實現顯著財務增長的可能性。</li>
<li>點擊這裏瞭解 Innodisk 的細節，查看我們的詳細財務健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c3a91485-32b6-4c06-ac57-53ee36cd1a5c/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/c3a91485-32b6-4c06-ac57-53ee36cd1a5c/chart/dcf?theme=light"/></p>
<p>TPEX:5289 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>TPEX:5289 截至 2026 年 1 月的折現現金流</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Navigate through the entire inventory of 259 Undervalued Asian Stocks Based On Cash Flows here.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏瀏覽基於現金流的 259 只被低估的亞洲股票的完整清單。</li>
<li>擁有這些公司的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>使用 Simply Wall St 的應用程序簡化您的投資策略，免費享受全球各地股票的廣泛研究。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>尋找新的視角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>通過顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章不應被視為財務建議。它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

亞洲價值股精選用於 2026 年 1 月的內在估值預測